Generic Portfolio Expansion

About X-gen Pharmaceuticals DJB

XGen Pharmaceuticals DJB is a commercial-stage, revenue-generating generic drug company with a strategy centered on acquiring and marketing stable-volume, limited-competition generic products. The company emphasizes its core strengths in supply chain logistics, regulatory compliance, and customer relationships, aiming to add 3-5 new products to its portfolio annually. As a private, family-run business, it leverages its flexibility and decades of collective industry experience to navigate the competitive generic pharmaceuticals market, supported by recent milestones like NABP accreditation.

About SPIMACO

SPIMACO's mission is to ensure a stable, secure supply of essential medicines for Saudi Arabia and the MENA region through advanced local manufacturing and strategic expansion. The company has achieved market leadership domestically, built a robust international footprint across 21 markets, and established itself as a critical partner in the Kingdom's healthcare transformation. Its strategy is deeply aligned with Vision 2030, focusing on vertical integration, technology transfer, talent development (Saudization), and leveraging its scale to capture growth in both domestic and export markets.

Therapeutic Areas